TABLE 4

Number of Participants Needed Per Arm to Detect Aβ-Modifying Treatment Effect in 12-Month Clinical Trial with 80% Power and 2-Tailed P of 0.05

No. of participants needed to detect…	Reference ROI	AD Aβ+	AD Aβ−	MCI Aβ+	MCI Aβ−	NC Aβ+	NC Aβ−	NC ε4+	NC ε4−
25% attenuation in further SUVR increases	Cerebral white matter	187	515	325	1,547	162	819	252	770
	Cerebellum	62,809	3,040	8,076	10,844	853	2,938	1,180	2,453
	Pons	N/A	N/A	2,718	724,200	697	3,318	907	2,519
25% decrease in SUVR from baseline	Cerebral white matter	8	21	13	62	7	33	11	31
	Cerebellum	2,513	122	324	434	35	118	48	99
	Pons	N/A	N/A	109	28,968	28	133	37	101